Zentalis pharmaceuticals to present preclinical azenosertib data at esmo 2024

Azenosertib shows synergistic anti-tumor effects in combination with topoisomerase i (top1) inhibitor-based antibody drug conjugates azenosertib shows synergistic anti-tumor effects in combination with topoisomerase i (top1) inhibitor-based antibody drug conjugates

TOP Ratings Summary

TOP Quant Ranking